GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to pre...
| GSK | Peers | Sector | |
|---|---|---|---|
Market Cap | 81.021 B | 74.044 B | 66.246 M |
Price % of 52 Week High | 86.1% | 84.2% | 62.6% |
Dividend Yield | 3.9% | 3.2% | 0.0% |
Shareholder Yield | 5.5% | 2.9% | -0.6% |
1 Year Price Total Return | -0.8% | -3.5% | -11.0% |
Beta (5 Year) | 0.29 | 0.36 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 35,449 | 38,662 | 39,282 | 10,265 | 10,162 |
| Operating Income | 8,851 | 10,712 | 7,742 | 2,168 | 1,248 |
| Net Profit | 18,080 | 6,282 | 3,224 | 446 | 518 |
| Diluted EPS | 1.32 | 1.53 | 0.78 | 0.11 | 0.13 |
| EBITDA | 11,234 | 13,136 | 10,408 | 2,462 | 1,914 |
| Balance Sheet | |||||
| Cash & ST Invest. | 10,547 | 7,251 | 5,416 | 7,251 | 5,416 |
| Current Assets | 25,107 | 23,768 | 21,280 | 23,768 | 21,280 |
| Total Assets | 72,709 | 75,220 | 74,446 | 75,220 | 74,446 |
| Current Liabilities | 27,574 | 26,858 | 27,164 | 26,858 | 27,164 |
| Total Liabilities | 60,504 | 58,909 | 58,063 | 58,909 | 58,063 |
| Total Equity | 12,205 | 16,311 | 16,383 | 16,311 | 16,383 |
| Total Debt | 25,371 | 22,970 | 21,266 | 22,970 | 21,266 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 8,949 | 8,628 | 8,205 | 4,074 | 2,916 |
| Cash From Investing | (10,604) | (2,033) | (1,539) | 342 | (1,401) |
| Cash From Financing | 995 | (7,191) | (5,917) | (4,579) | (1,054) |
| Free Cash Flow | 7,568 | 6,953 | 6,454 | 3,455 | 2,235 |